{Reference Type}: Case Reports
{Title}: Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
{Author}: Schmalz L;Bloomer C;Zhang W;Petty W;
{Journal}: Lung Cancer
{Volume}: 186
{Issue}: 0
{Year}: 2023 12 11
{Factor}: 6.081
{DOI}: 10.1016/j.lungcan.2023.107400
{Abstract}: Targeted therapies have revolutionized treatment for metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations. However, challenges arise in managing concurrent mutations and overcoming resistance. We present the case of a patient with epidermal growth factor receptor (EGFR) (L747_A750delinsP exon19 deletion) and mesenchymal-epithelial transition factor (MET) mutations (D1228H, D1228N, D1228Y, Y1230H, MET amplification) who achieved a durable response to amivantamab (14 months ongoing) after progression on multiple lines of therapy including platinum-based chemotherapy, EGFR tyrosine kinase inhibitors (TKI) and combination TKI and MET inhibitors. This case highlights the utility of longitudinal next-generation sequencing (NGS) testing to identify acquired resistance and the need for continued research into understanding mechanisms of resistance to help develop future treatment strategies.